A Prospective Single Center Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With AL Amyloidosis
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Complete response (CR) rate
研究概览
简要总结
The treatment with oral melphalan and prednisone has been recommended as standard treatment of AL amyloidosis but the results are rather disappointing. Another therapeutic option is pulsed high-dose dexamethasone + melphalan (Mel-Dex) with more encouraging results regarding the achievement of a faster disease response and higher rates of haematological remission. In the last 5 - 10 years, promising treatment outcomes after therapy with high-dose melphalan and autologous stem cell support have been reported by several groups but only highly selected patients are eligible for this treatment. Lenalidomide has been shown to be effective in phase II and III trials in MM patients. Because of the relationship to MM, Lenalidomide is a promising therapeutic option also for patients with AL amyloidosis. The addition of Lenalidomide to Mel-Dex could improve rate of complete response (CR) and organ response in patients not eligible for or refused high-dose chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biopsy proven systemic untreated AL amyloidosis requiring systemic chemotherapy
- •Not eligible for or refused HDM
- •Measurable plasma cell disease
- •Life expectancy > 3 months
- •WHO performance status < 3
- •NYHA < stage IV
- •Understand and voluntarily sign an informed consent form
- •Laboratory test results within these ranges Absolute neutrophil count > 1.5 x 109/L Platelet count > 100 x 109/L Creatinine Clearance / MDRD > 40 ml/min Total bilirubin > 2,5 mg/dL
- •Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study.
排除标准
- •Multiple Myeloma stage II and III (Durie and Salmon)
- •Previous organ transplantation
- •Not able to visit the Amyloid Clinic in Heidelberg once per month
- •Refusal of aspiration of 100 ml bone marrow at study inclusion
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- •Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- •Use of any other experimental drug or therapy within 28 days of baseline.
- •Known hypersensitivity to thalidomide.
- •The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- •Any prior use of lenalidomide.
- •Concurrent use of other anti-cancer agents or treatments.
- •Known positive for HIV or infectious hepatitis, B or C.
- •Patients who are in a depending position of the Sponsor or the Principal Investigator
研究组 & 干预措施
Treatment Arm
Treatment Arm
干预措施: Lenalidomide (Drug)
结局指标
主要结局
Complete response (CR) rate
时间窗: 6 months: after 6 cycles of L-Mel-Dex
次要结局
- Organ response rate(3 months after discontinuation of L-Mel_Dex (maximum: 9 months))
- Correlation of cytogenetic aberrations and gene expression profiling (GEP) results with best hematological response to treatment(6 months)
- Retrospective comparison with a historical control group treated with Mel-Dex in our institution(01.04.2012)
- Rate of hematological response (CR and PR)(6 months)
- Toxicity (hematological and non-hematological)(6 months)
研究者
Dr. Stefan Schönland
MD
Heidelberg University